| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | GUCY1A3; GC-S-alpha-1; GUC1A3; GUCA3; GCS-alpha-3; GUCY1A1; GC-SA3; GCS-alpha-1; GUCSA3;;GCS alpha 1 |
| WB Predicted band size | Calculated MW: 77 kDa ; Observed MW: 73 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human GCS alpha 1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于GCYA3抗体的模拟参考文献示例(注：GCYA3可能为假设或非标准缩写，建议核实术语准确性)：
1. **文献名称**: "Characterization of GCYA3-Specific Antibodies in Retinal Signaling Pathways"
**作者**: Smith J, et al.
**摘要**: 本研究开发了针对GCYA3(推测为视网膜特异性鸟苷酸环化酶亚型)的多克隆抗体，证实其在光信号转导中的作用，抗体通过免疫印迹和免疫组化验证特异性。
2. **文献名称**: "GCYA3 Antibody Application in Cardiovascular Disease Models"
**作者**: Lee H, et al.
**摘要**: 文章报道了一种单克隆抗体的生成，用于检测心血管组织中GCYA3的表达，并发现其与高血压病理的相关性，抗体特性通过流式细胞术验证。
3. **文献名称**: "GCYA3 as a Novel Biomarker: Validation via Custom Antibody Assays"
**作者**: Garcia R, et al.
**摘要**: 该研究利用新开发的GCYA3抗体进行ELISA检测，发现其在肿瘤微环境中的异常表达，提示其作为癌症诊断标志物的潜力。
**注意**：上述文献为示例性质，实际研究中“GCYA3”可能并非标准术语。建议通过基因数据库(如NCBI Gene)确认目标分子标准命名(如GUCY3A等)，并检索相关文献。
The GCYA3 antibody is designed to target guanylyl cyclase A3 (GC-A3), a membrane-bound receptor enzyme that plays a critical role in cellular signaling by converting GTP to cyclic GMP (cGMP). GC-A3 is part of the natriuretic peptide receptor family, primarily binding atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) to regulate blood pressure, fluid homeostasis, and cardiovascular function. Dysregulation of GC-A3 activity has been implicated in hypertension, heart failure, and renal disorders, making it a focus of cardiovascular and metabolic research.
The GCYA3 antibody is typically developed in animal models (e.g., rabbits or mice) using immunogenic peptides or recombinant protein fragments. It enables detection and quantification of GC-A3 expression in tissues like the heart, kidneys, and vasculature via techniques such as Western blotting, immunohistochemistry, and ELISA. Validation often includes knockout controls or siRNA knockdown to confirm specificity. Researchers utilize this tool to explore GC-A3's signaling mechanisms, its interaction with ligands, and its pathophysiological roles in disease models. Recent studies also investigate its potential as a therapeutic target, particularly in conditions linked to cGMP pathway dysfunction.
×
